8-K: Gilead to Acquire Arcellx for $7.8B, Boosting Cell Therapy

Gilead Sciences announced a definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion, gaining full control of the promising BCMA-directed CAR T-cell therapy anito-cel for multiple myeloma.

Summary

• Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx, Inc. for an implied equity value of $7.8 billion.
• The acquisition consideration includes $115.00 per share in cash at closing and one non-transferable Contingent Value Right (CVR) of $5.00 per share.
• The CVR payment is contingent upon anito-cel achieving cumulative global net sales of at least $6.0 billion from launch through year-end 2029.
• Gilead currently owns approximately 11.5% of Arcellx's outstanding common stock.
• The transaction builds on an existing 2022 collaboration between Kite (a Gilead company) and Arcellx for the co-development and co-commercialization of anitocabtagene autoleucel (anito-cel).
• This acquisition provides Gilead with full control of anito-cel, eliminating previous profit-share, milestones, and royalties from the collaboration.
• The U.S. Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for anito-cel as a fourth-line treatment for relapsed or refractory multiple myeloma, with an anticipated Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026.
• The transaction is anticipated to close during the second quarter of 2026, subject to customary closing conditions, including the tender of a number of Arcellx common shares that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares, and regulatory approvals.
• Upon FDA approval of anito-cel, the proposed transaction is expected to be accretive to Gilead's earnings per share in 2028 and thereafter.
• Arcellx's D-Domain CAR technology platform, which generated anito-cel, is also highlighted for its potential in next-generation CAR T-cell and bispecific therapies, and in vivo cell therapy efforts.
• A termination fee of $260,000,000 is payable by Arcellx to Gilead under specified circumstances, including termination by Arcellx to accept a superior offer.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive strategic move for Gilead, securing a promising late-stage cell therapy asset with strong clinical data and regulatory progress, while offering a substantial premium to Arcellx shareholders.

Positives

• Gilead gains full control of anito-cel, a potentially transformative CAR T-cell therapy for multiple myeloma, eliminating prior profit-share, milestones, and royalties.
• Anito-cel has demonstrated deep and durable responses with a predictable and manageable safety profile in clinical studies.
• The FDA accepted the BLA for anito-cel, with a PDUFA date of December 23, 2026, indicating strong progress towards commercialization.
• The acquisition strengthens Gilead's oncology and inflammation pipeline, particularly in the high-growth cell therapy space.
• Arcellx's D-Domain CAR technology platform offers potential for future next-generation therapies.
• The transaction is expected to be accretive to Gilead's EPS in 2028 and beyond, following FDA approval.
• Support agreements from Arcellx directors, executive officers, and certain institutional investors (approximately 10.3% of shares) commit them to tender their shares and vote for the merger.

Negatives

• The CVR payment of $5.00 per share is contingent on achieving cumulative global net sales of anito-cel of at least $6.0 billion by December 31, 2029, which may not be achieved.
• Arcellx is subject to a $260,000,000 termination fee if the merger agreement is terminated under specific circumstances, such as accepting a superior offer.
• The CVRs are non-transferable except under limited circumstances and will not be registered with the SEC or listed for trading, limiting liquidity for holders.

Risks

• Uncertainties as to the timing of the tender offer and merger.
• Uncertainties as to how many of Arcellx's stockholders will tender their stock in the offer.
• The possibility that competing offers will be made.
• The possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction.
• The effects of the transaction on relationships with employees, other business partners or governmental entities.
• The difficulty of predicting the timing or outcome of regulatory approvals or actions, if any.
• The risk that, if the transaction is consummated, the businesses will not be integrated successfully and that other anticipated benefits from the transaction will not be realized.
• Any negative effects on the existing collaboration between Arcellx and Gilead that may result from the announcement of a transaction, or the failure to complete the transaction.
• The risk that the milestone associated with the CVR may not be achieved and that holders of CVRs may not receive payments in respect thereof.
• The impact of competitive products and pricing.
• Transaction costs and actual or contingent liabilities.
• Potential payouts of the CVR are subject to various risks and uncertainties related to the development, regulatory approvals, commercialization of anito-cel, and third-party patent claims.

Future Outlook

Gilead anticipates anito-cel could become a foundational treatment for multiple myeloma, including earlier lines of therapy, following its potential commercial launch in 2026. The transaction is expected to streamline preparation and accelerate adoption and access to anito-cel, and be accretive to Gilead's earnings per share in 2028 and thereafter, upon FDA approval. Arcellx's D-Domain CAR technology platform also holds potential for future next-generation CAR T-cell and bispecific therapies.

Management Comments

• "This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma." Daniel O'Day, Chairman and CEO, Gilead Sciences.
• "Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy." Daniel O'Day, Chairman and CEO, Gilead Sciences.
• "The anito-cel D-domain BCMA binder could be important to our work in in vivo cell therapy, further strengthening our potential in oncology and inflammation." Daniel O'Day, Chairman and CEO, Gilead Sciences.
• "The story of Arcellx is one of innovation, passion, resilience and teamwork. I could not be prouder of our team, our contribution to the myeloma field, and the impact anito-cel and our D-Domain platform are poised to have for patients and clinicians." Rami Elghandour, Chairman and CEO, Arcellx.
• "We are fortunate to have found a world-class partner in Gilead, which has the expertise to carry forward Arcellx’s legacy. Kite is well-positioned to maximize access to anito-cel, benefiting more patients, and the company’s commitment to be the leader in cell therapy is one I admire." Rami Elghandour, Chairman and CEO, Arcellx.

Industry Context

StockSavvy.ai notes that this acquisition reinforces the ongoing consolidation and strategic investments within the biopharmaceutical sector, particularly in high-growth areas like cell therapy and oncology. Gilead's move to fully acquire Arcellx, following an earlier collaboration, highlights the increasing value placed on proprietary CAR T-cell technologies and the competitive landscape for innovative treatments in multiple myeloma. This transaction positions Gilead to strengthen its leadership in cell therapy, a field seeing rapid advancements and significant M&A activity as larger players seek to integrate promising pipeline assets.

Comparison to Industry Standards

• The acquisition price of $115 per share in cash represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026, which is a substantial premium, indicating strong conviction in anito-cel's value.
• The inclusion of a non-transferable CVR is a common mechanism in biotech acquisitions to bridge valuation gaps and incentivize the achievement of specific commercial milestones, aligning seller and buyer interests post-acquisition.
• Anito-cel's clinical profile, demonstrating deep and durable responses with a manageable safety profile, positions it competitively against existing CAR T-cell therapies for multiple myeloma, such as Johnson & Johnson's Carvykti (ciltacabtagene autoleucel) and Bristol Myers Squibb's Abecma (idecabtagene vicleucel), which have also shown strong efficacy but carry their own safety considerations.
• Gilead's expectation of EPS accretion by 2028, post-FDA approval, suggests a strategic financial rationale for the acquisition, typical for established pharmaceutical companies integrating late-stage assets.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions that Arcellx stockholders may bring litigation related to the agreement, offer, or merger, and the company will notify Parent and allow participation in defense.

Related Party Transactions

• Gilead currently owns approximately 11.5% of Arcellx's outstanding common stock, making it a significant existing shareholder and collaboration partner.
• Tender and Support Agreements were entered into with directors, executive officers, and certain institutional investors (affiliated with New Enterprise Associates and SR One Capital Fund I Aggregator, L.P.) of Arcellx, who collectively own approximately 10.3% of outstanding shares, committing them to tender their shares in the offer.

Stakeholder Impact

• Shareholders (Arcellx): Will receive $115.00 per share in cash plus a contingent value right of $5.00 per share, representing a significant premium. Those holding Company Options and RSUs will also receive cash and CVRs.
• Shareholders (Gilead): Expected to benefit from the acquisition being accretive to EPS by 2028 and the strengthening of Gilead's cell therapy pipeline.
• Employees (Arcellx): Parent commits to providing comparable cash opportunity and broad-based benefits (excluding certain types) for a period post-merger. Directors and officers will resign but retain indemnification rights.
• Customers/Patients: The acquisition aims to accelerate the development and commercialization of anito-cel, potentially benefiting patients with multiple myeloma by providing a new treatment option more quickly.
• Regulatory Bodies: The transaction is subject to regulatory approvals, including under the HSR Act and foreign antitrust laws.

Next Steps

• Purchaser (Gilead's subsidiary) will commence a tender offer to acquire outstanding Arcellx shares.
• Satisfaction or waiver of customary closing conditions, including tender of a majority of Arcellx shares and regulatory approvals.
• Closing of the transaction is anticipated during the second quarter of 2026.
• Following the tender offer, a second-step merger will acquire any remaining Arcellx shares.
• FDA review of anito-cel BLA with an anticipated PDUFA action date of December 23, 2026.
• Gilead will work to integrate Arcellx's business and accelerate the development and commercialization of anito-cel.
• Arcellx will take actions to terminate its 401(k) plan and Sales Agreement prior to closing.
• Arcellx will use commercially reasonable efforts to cause its CEO to enter into a non-competition agreement with Parent prior to the Closing Date.

Key Dates

Recommendation

For Arcellx shareholders, the offer represents a substantial premium over recent trading prices, providing a strong immediate return and potential upside via the CVR. For Gilead, this acquisition is a strategic imperative, securing full control of a late-stage, potentially transformative CAR T-cell therapy (anito-cel) that has demonstrated strong clinical results and is on track for FDA review. The deal strengthens Gilead's oncology pipeline, particularly in the high-growth cell therapy space, and is expected to be accretive to earnings, making it a compelling long-term investment.

Keywords

Gilead Sciences, Arcellx, Acquisition, Merger, Anito-cel, CAR T-cell therapy, Multiple Myeloma, Biotechnology, Oncology, Cell Therapy, Contingent Value Right, CVR, FDA Approval, PDUFA, Tender Offer, Biologic License Application, BCMA-directed therapy, D-Domain CAR technology